Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Design

Volume 19 Issue 4
ISSN: 1381-6128
eISSN: 1873-4286

 

   All Titles

  Rejuvenating Sirtuins: The Rise of a New Family of Cancer Drug Targets
  pp.614-623 (10) Authors: Santina Bruzzone, Marco Daniele Parenti, Alessia Grozio, Alberto Ballestrero, Inga Bauer, Alberto Del Rio, Alessio Nencioni
 
 
      Abstract

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.

 
  Keywords: Sirtuin modulators, cancer, drug design, epigenetics, drug discovery
  Affiliation: Room 221, Department of Internal Medicine, University of Genoa, V.le Benedetto XV 6, 16132 Genoa, Italy.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers